Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
- 1119.931
- +0.354+0.03%
Gilead Sciences First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Bristol-Myers Squibb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Biogen Inc. (NASDAQ:BIIB) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Express News | Novartis innovates PNH oral monotherapy Feheda (ipcopam hydrochloride capsules) approved in China
Eliminates hundreds of treatments! Pfizer (PFE.US) gene therapy approved for listing by FDA
Pfizer/PFE.us (Pfizer/PFE.us) announced that the US FDA has approved the single-use gene therapy Beqvez (fidanacogene elaparvovec) it has developed to treat adults with moderate to severe hemophilia B aged 18 or above.
Analysts Are Neutral on These Healthcare Stocks: Edwards Lifesciences (EW), Gilead Sciences (GILD)
Express News | Novartis's innovative drug for rare diseases has been approved domestically. It is the first oral monotherapy for PNH treatment in adults
Gilead Sciences To Go Ex-Dividend On June 14th, 2024 With 0.77 USD Dividend Per Share
April 27th - $Gilead Sciences(GILD.US)$ is trading ex-dividend on June 14th, 2024. Shareholders of record on June 14th, 2024 will receive 0.77 USD dividend per share on June 27th, 2024. The ex-div
Pfizer Options Spot-On: On April 26th, 118.91K Contracts Were Traded, With 3.21 Million Open Interest
On April 26th ET, $Pfizer(PFE.US)$ had active options trading, with a total trading volume of 118.91K options for the day, of which put options accounted for 37.64% of the total transactions, and call
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Health care stocks were advancing late Friday afternoon, with the NYSE Health Care Index adding 0.2% and the Health Care Select Sector SPDR Fund (XLV) up 0.1%. The iShares Biotechnology ETF (IBB) rose
Gilead Sciences Unusual Options Activity
Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:GILD), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga un
More Than Half of the S&P 500 Names That Reported Results This Week Beat Top and Bottom Line - Earnings Scorecard
FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia
Friday, the FDA approved Pfizer Inc's (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or h
Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
Bristol-Myers Squibb Price Target Cut to $48.00/Share From $55.00 by BMO Capital
Bank of Montreal, Canada: Maintaining the Bristol-Myers Squibb (BMY.US) rating, adjusted from a consistent market rating to a consistent market rating, and the target price was adjusted from $55.00 to $48.00.
Bank of Montreal, Canada: Maintaining the Bristol-Myers Squibb (BMY.US) rating, adjusted from a consistent market rating to a consistent market rating, and the target price was adjusted from $55.00 to $48.00.
$3.5 million per dose! US FDA Approves Pfizer's One-Time Gene Therapy for Hemophilia B
① Beqvez is a one-off treatment that enables patients to produce coagulation factor IX and prevent bleeding; ② Pfizer's drugs have the potential to have a transformative impact on patients by reducing long-term medical and treatment burdens.
Gilead Sciences Price Target Cut to $85.00/Share From $90.00 by TD Cowen
Gilead Sciences Price Target Cut to $85.00/Share From $90.00 by TD Cowen
19 Out 20 S&P 500 Healthcare Companies Beat Profit Estimates - Earnings Scorecard
Pfizer Pharmaceuticals rose more than 1% to a new high of $25.53, and the US Food and Drug Administration approved its first-generation treatment for a rare hereditary hemorrhagic disease.
Pfizer Pharmaceuticals rose more than 1% to a new high of $25.53, and the US Food and Drug Administration approved its first-generation treatment for a rare hereditary hemorrhagic disease.
Pfizer (NYSE:PFE) Notches Up on New FDA Approval